Clinical Trials Logo
  1. Home
  2. Asthma
  3. NCT06330974
  4. Details
NCT06330974 Clinical Trial

Allergy, Asthma, and Atopic Eczema in Finland

Asthma Clinical Trial

— FinnATOPY  

Official title:
Allergy, Asthma, and Atopic Eczema in Finland - A Nationwide Study on Prevalence, Comorbidities, Treatment and Economic Burden

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06330974
Other study ID # FinnATOPY
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date October 2024
Est. completion date December 2034

Study information
Verified date March 2024
Source Tampere University
Contact Péter Csonka, MD, PhD
Phone +358503661103
Email peter.csonka@tuni.fi
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The summary is available at --> https://www.finnatopy.fi/summary

Description:

Aims and objectives ---> https://www.finnatopy.fi/aims-and-objectives Methods ---> https://www.finnatopy.fi/methods

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 2000000
Est. completion date December 2034
Est. primary completion date December 2032
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion/Exclusion Criteria ---> https://www.finnatopy.fi/methods

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• No intervention
No intervention

Locations
Country Name City State
Finland Tampere University Tampere

Sponsors (5)
Lead Sponsor Collaborator
Tampere University Professor Ilkka Junttila, Professor Lauri Lehtimäki, Professor Mika Mäkelä, Professor Sanna Toppila-Salmi

Country where clinical trial is conducted

Finland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Epidemiology of atopic diseases and allergic sensitization profiles in Finland Incidence and prevalence of asthma, specific IgE sensitization, atopic dermatitis, allergic rhinitis 7 years
Primary Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland Morbidity, sick leaves, medication use, costs and expences 7 years
Primary Evaluate and improve the current use of diagnostic tests for atopic diseases Diagnostic practices, tests for allergic sensitization, lung function tests, and other laboratory measures. 7 years
Primary Use and effectiveness of allergen immunotherapy in real world setting Real world evidence data using specific cohorts 7 years
Primary Direct and indirect costs related to atopic diseases and comorbidities All costs, including sick leaves, absenteeism, laboratory costs, other diagnisteic tests, etc. 7 years
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device